David A Hammond

US Patent:

7217507, May 15, 2007

Filed:

Apr 14, 2003

Appl. No.:

10/414523

Inventors:

David J. Hammond - Laytonsville MD, US
Julia Tait Lathrop - Falls Church VA, US

Assignee:

The American National Red Cross - Falls Church VA

International Classification:

C12Q 1/70
C12Q 1/68
C12Q 1/46

US Classification:

435 5, 435 6, 435 20

Abstract:

The invention provides a method of characterizing a target that binds to a ligand. The method comprises providing ligands, optionally attached to a support, and contacting the ligands with targets to allow at least one target to bind to at least one ligand. The method further comprises immobilizing the resulting complexes in a first matrix, such that each complex has a different position within the first matrix, and transferring the target of the complex to a second matrix. The position of the target within the second matrix corresponds to the position of the ligand-support complex within the first matrix. The target on the second matrix is then detected.

US Patent:

7223734, May 29, 2007

Filed:

Apr 14, 2003

Appl. No.:

10/414524

Inventors:

David J. Hammond - Laytonsville MD, US
Julia Tait Lathrop - Falls Church VA, US
Iwona Fijalkowska - Rockville MD, US

Assignee:

The American National Red Cross - Falls Church VA

International Classification:

A61K 38/08
C07K 7/04
C07K 2/00

US Classification:

514 17, 514 2, 530300, 530329

Abstract:

The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa-Xaa-Xaa-Xaa-Xaa, an amino acid sequence Gly-Xaa-Arg-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to αl proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa-Xaa-Xaa-His-Xaa-Xaa, and amino acid sequence His-Xaa-Xaa-Xaa-Xaa-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa-Xaa-Xaa, an amino acid sequence Tyr-Leu-Xaa-Xaa-Xaa-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.

US Patent:

7374900, May 20, 2008

Filed:

Mar 16, 2004

Appl. No.:

10/553650

Inventors:

Serguei Soukharev - Derwood MD, US
David Hammond - Laytonsville MD, US

Assignee:

The American National Red Cross - Rockville MD

International Classification:

C12Q 1/42
C07F 9/12

US Classification:

435 21, 549220

Abstract:

Disclosed are compounds of the formula (I): wherein R, R, R, R, and Rare selected from the group consisting of H and groups or atoms other than H, and Rand Rare halo or hydrogen; X, X, and Xare independently O or S; provided that Rand Rare not simultaneously H, when all of X, X, and Xare O; and of the formula (II) wherein R-Rare selected from the group consisting of H and groups or atoms other than H; X-Xare independently O or S; n and m are 0 or 1 but m and n cannot be 0 simultaneously; R-Rcan be H or any substituent so long as the compound of formula II upon hydrolysis provides a fluorescent compound. These compounds are useful as substrates with high specificity for organophosphatase particularly human paraoxonase and bacterial organophosphorus hydrolase. Also disclosed is a method for detecting and/or measuring the paraoxonase activity in a fluid comprising contacting the fluid with a fluorescent substrate and measuring the fluorescence of the fluorescent product formed.

US Patent:

7510848, Mar 31, 2009

Filed:

Oct 13, 2004

Appl. No.:

10/962670

Inventors:

David J. Hammond - Laytonsville MD, US
Ruben G. Carbonell - Raleigh NC, US
Honglue Shen - Raleigh NC, US
Patrick V. Gurgel - Cary NC, US
Steven J. Burton - Cambridge, GB

Assignee:

North Carolina State University - Raleigh NC
Pathogen Removal and Diagnostic Technologies Inc. - Washington DC

International Classification:

G01N 33/53
G01N 33/68
A61K 39/00
C12N 15/00

US Classification:

435 78, 435 693, 4242041, 424184, 4242481

Abstract:

Prion protein binding materials and methods for using the binding materials to detect or remove a prion protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), recombinant prion protein (PrPr), and proteinase resistant prion protein (PrPres). Prions from various species, including humans and hamsters, are bound by the binding materials.

US Patent:

7863411, Jan 4, 2011

Filed:

Dec 3, 2003

Appl. No.:

10/727335

Inventors:

David J. Hammond - Laytonsville MD, US
Julia T. Lathrop - Falls Church VA, US
Larisa Cervenakova - Rockville MD, US
Ruben G. Carbonell - Raleigh NC, US

Assignee:

Pathogen Removal and Diagnostics Technologies Inc. - Wilmington DE
North Carolina State University - Raleigh NC

International Classification:

C07K 5/00

US Classification:

530300

Abstract:

Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject.

US Patent:

8604161, Dec 10, 2013

Filed:

Feb 22, 2008

Appl. No.:

12/035917

Inventors:

David J. Hammond - Laytonsville MD, US
Julia T. Lathrop - Falls Church VA, US
Larisa Cervenakova - Rockville MD, US
Ruben G. Carbonell - Raleigh NC, US

Assignee:

Pathogen Removal and Diagnostic Technologies Inc. - Wilmington DE
North Carolina State University - Raleigh NC

International Classification:

C07K 5/00

US Classification:

530300

Abstract:

Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject.

US Patent:

20040101830, May 27, 2004

Filed:

Jun 20, 2003

Appl. No.:

10/601032

Inventors:

David Hammond - Laytonsville MD, US
Julia Lathrop - Falls Church VA, US
Jolly Sarkar - Olney MD, US
Liliana Gheorghiu - Bethesda MD, US

Assignee:

The American National Red Cross - Falls Church VA

International Classification:

C12Q001/70
C12Q001/68
G01N033/53
G01N033/567
G01N033/569
G01N033/554

US Classification:

435/005000, 435/006000, 435/007100, 435/007310, 435/007320, 435/007200

Abstract:

A method of screening a mixture for active entities, which method comprises: providing a plurality of ligands, wherein each ligand is attached to a support to form a plurality of ligand-support complexes, contacting the ligand-support complexes with a mixture comprising a plurality of entities under conditions that allow at least one entity to bind to at least one ligand-support complex, thereby forming at least one entity-ligand-support complex, separating at least one entity-ligand-support complex from the unbound entities, assaying at least one entity of at least one entity-ligand-support complex for an activity, detecting the activity, and selecting at least one entity-ligand-support-complex having the entity, which exhibited the detected activity, whereupon a mixture is screened for active entities; and related methods.

US Patent:

20050244866, Nov 3, 2005

Filed:

Mar 23, 2005

Appl. No.:

11/089128

Inventors:

Egisto Boschetti - Crossy sur Seine, FR
David Hammond - Laytonsville MD, US

Assignee:

Ciphergen Biosystems, Inc. - Fremont CA

International Classification:

C12Q001/68
G01N033/53

US Classification:

435006000, 435007100

Abstract:

The present invention relates to the fields of molecular biology, combinatorial chemistry and biochemistry. Particularly, the present invention describes methods and kits for dynamically reducing the variance between analyte taken from complex mixtures.